Company attributes
Other attributes
Emergex Vaccines is a company pioneering a new approach to vaccine development and manufacturing using cutting-edge technologies to produce novel synthetic vaccines intended to fight against viral and bacterial infectious diseases. The company develops synthetic non-biological components that prime immune cells to destroy pathogen-infected cells for diseases that include dengue fever, zika, ebola and pandemic flu as well as serious intra-cellular bacterial infections.
Emergex aims to offer affordable, practical and effective vaccines on-demand, which are suited to low resource environments, disproportionately affected by pandemics. These vaccines will be used to create a clinical-grade international vaccine repository to act as a first line of defense in the case of existing and newly emerging infectious disease outbreaks.
Technology developed by Emergex has successfully been used in the development of the company’s current viral vaccine candidates which includes Dengue Fever and potentially other flaviviruses, pandemic and seasonal Influenza (flu) and filoviruses such as Ebola virus.
In December 2019, Emergex announced the completion of the first step in the development of a vaccine candidate against intracellular bacterium and bioterrorist agent francisella tularensis. This is the first time that Emergex’s technology has been successfully applied in the creation of a bacterial vaccine candidate.
The company based in Abingdon, Oxfordshire, was founded in 2016 by Thomas Rademacher (CEO) and Storme Moore-Thornicroft (Executive Director & COO). Rademacher is Professor Emeritus of molecular medicine at the University College London Medical School and has founded and led several successful biotechnology companies. Moore-Thornicroft previously founded Midiatech Pharma PLC, she specializes in entity incorporation, corporate and business strategy.
The company has raised a total of $12.3M in 2 rounds of funding. In May 2018 a $1.3M grant from Innovate UK, part of UK Research and Innovation (UKRI) the government's national funding agency investing in science and research. In January 2020, Emergex raised $11M in Series A funding led by Vickers Venture Partners. Dr. Finian Tan, chairman of Vickers Venture Partners, has joined Emergex’s board of directors.
